ArticleThe journal of headache and pain2025
A prospective real-world analysis of intravenous eptinezumab in migraine management: the first UK experience.
Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Persistence and Reasons for Treatment Discontinuation of Anti-CGRP Therapies in Migraine Prophylaxis: A Systematic Review and Meta-analysis of Real-World Studies.Pain and therapy · 2026Review
- Article
- Twelve-months prospective real-world assessment of effectiveness and safety of eptinezumab in migraine patients difficult-to-treat and naïve to CGRP monoclonal antibodies: results of the French FHU INOVPAIN registry.The journal of headache and pain · 2026Article
- Cross-response to Calcitonin Gene-Related Peptide monoclonal antibodies in a real-world setting: analysis of prospective data collected in the French FHU InovPain registry.The journal of headache and pain · 2026Article
- Identifying cardiac safety signals of disproportionate reporting for CGRP antagonists: evidence from the FDA Adverse Event Reporting System.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Eptinezumab to prevent difficult-to-treat migraine: prospective, six-month, real-world multicenter evidence from the GRASP study group.The journal of headache and pain · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials have shown the safety and statistical superiority of intravenous eptinezumab to placebo in migraine prevention in adults. However, data in real-world settings is sparse.
methodsThis is a prospective open-label single centre real-world analysis aiming to establish the effectiveness of intravenous eptinezumab 100 mg in patients with migraine who were treated for up to six months as per the National Institute of Care and Health Excellence (NICE) guidelines in the United Kingdom (UK).
resultsOf 130 patients treated between February 2023 and February 2025, 119 patients with migraine (chronic migraine: 112, 94%), who had completed a three month follow up and submitted their headache diary following the first eptinezumab infusion were analysed. Patients failed to respond/tolerate an average of 10.2 ± 4.5 preventive treatments and 80 patients (67%) did not respond or tolerate one or two calcitonin gene related peptide (CGRP) targeting therapies prior to Eptinezumab. After one eptinezumab infusion, 61 (51%), 41 (35%) and 15 (13%) of patients achieved at least a 30%, 50% and 75% reduction in their mean monthly migraine days (MMDs), respectively. The average reduction in MMD was 5.4 days (P < 0.001). Out the 76 patients who had the six-month review after the second infusion, 48 (63%), 33 (43%) and 14 (18%) of patients achieved at least a 30%, 50% and 75% reduction, respectively, in their MMD, with an average reduction in MMD of 6.3 days (P < 0.001). There was an average reduction of the Headache Impact Test 6 (HIT-6) score of 5.3 and 6.3 respectively at months 3 and 6 post-infusions (P < 0.001). Patients who were naive to any other anti-CGRP monoclonal antibodies (mAb) treatment were more likely to be eptinezumab responders (30% reduction in MMD) than those who failed to respond to previous anti-CGRP mAbs both at 3 and 6 months (3 month responders: 74% vs. 40; 6 months responders: 56% vs. 33%, p = 0.001). After the first treatment, 24 patients (20%) reported 34 treatment-related adverse events. After the second treatment, nine patients reported ten adverse events. Six patients (5%) discontinued eptinezumab because of side effects.
conclusionIn real world settings, intravenous eptinezumab may be an effective and well tolerated treatment option for patients with migraine who fail multiple treatments including other anti-CGRP mAbs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.